GlassScriptPhysician profile
Arun Adlakha
NPI 1366435422
$183,718.10
in general payments reported to CMS, 2019-2025
38 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $30K · 2021: $32K · 2022: $9,944 · 2023: $28K · 2024: $16K · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $5,133 · Consulting Fee: $4,120 · Travel and Lodging: $1,665 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,910.00 |
| Food and Beverage | $5,132.60 |
| Consulting Fee | $4,120.00 |
| Travel and Lodging | $1,664.82 |
| Education | $138.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $100,648.89 | 2019-2024 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $26,930.57 | 2019-2024 | Yupelri |
| Genzyme Corporation | $24,210.54 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $14,761.26 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $4,147.50 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Astrazeneca Pharmaceuticals LP | $3,864.73 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Paratek Pharmaceuticals, INC. | $1,762.29 | 2022-2023 | Nuzyra |
| Glaxosmithkline, LLC. | $1,696.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols Shared Services North America, INC. | $1,640.00 | 2023 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $717.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $683.08 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Genentech USA, INC. | $426.44 | 2019-2022 | |
| United Therapeutics Corporation | $364.42 | 2021-2025 | Tyvaso, Tyvaso |
| Pfizer INC. | $324.90 | 2021-2025 | |
| Insmed, INC. | $266.98 | 2019-2025 | Arikayce |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $170.24 | 2019-2023 | Opsumit, Uptravi |
| Verona Pharma, INC. | $155.63 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $111.82 | 2020-2023 | Acthar |
| Circassia INC. | $94.89 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $94.33 | 2019-2025 | |
| Baxter Healthcare | $86.74 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $81.37 | 2019-2020 | |
| Advanced Respiratory, INC | $78.42 | 2019-2021 | |
| Csl Behring | $64.96 | 2019-2025 | Hizentra |
| Shire North American Group INC | $49.04 | 2019 | |
| Philips North America LLC | $47.41 | 2023 | |
| Novartis Pharmaceuticals Corporation | $33.84 | 2019 | |
| Amgen INC. | $33.35 | 2022 | |
| Tersera Therapeutics LLC | $33.10 | 2022 | |
| Mallinckrodt Enterprises LLC | $32.12 | 2019 | |
| Covis Pharma Gmbh | $30.61 | 2022 | |
| Merck Sharp & Dohme LLC | $29.38 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $18.07 | 2022 | |
| Daiichi Sankyo INC. | $15.80 | 2019 | |
| Astellas Pharma US INC | $11.44 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Adlakha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.